Events

Sanofi-sponsored symposium originally presented at SEMDSA 2025, now available on-demand. In this engaging session, leading experts delve into the critical decision points along the Type 2 Diabetes patient journey and the evolving role of Fixed-Ratio Combination (FRC) therapies. Explore real-world patient challenges and gain a deeper understanding of how FRCs can simplify treatment, improve adherence, and support better outcomes. The session also features a comparative analysis of the latest efficacy and safety data on iGlarLixi (insulin glargine/lixisenatide) versus iDegAsp (insulin degludec/aspart) in non-Asian populations—shedding light on practical considerations for clinical use.